A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

[1]  S. Kerpel-Fronius.  Cisplatin and its Analogues for Cancer Chemotherapy , 2006 .

[2]  N. Senzer,et al.  Irofulven Demonstrates Clinical Activity Against Metastatic Hormone-Refractory Prostate Cancer in a Phase 2 Single-Agent Trial , 2005, American journal of clinical oncology.

[3]  M. Elman,et al.  Characterization and Multiparameter Analysis of Visual Adverse Events in Irofulven Single-Agent Phase I and II Trials , 2004, Clinical Cancer Research.

[4]  E. Raymond,et al.  Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor Patients , 2004, Clinical Cancer Research.

[5]  E. Raymond,et al.  Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. , 2003, International journal of oncology.

[6]  E. Raymond,et al.  Phase I population pharmacokinetics of irofulven , 2003, Anti-cancer drugs.

[7]  Huiyun Liang,et al.  Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent. , 2003, Biochemical pharmacology.

[8]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[9]  M. Hidalgo,et al.  Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Hidalgo,et al.  Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Woynarowski,et al.  Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). , 2000, Biochemical pharmacology.

[12]  M. Kelner,et al.  Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft , 2000, Anti-cancer drugs.

[13]  D. Stewart,et al.  Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. , 1999, American journal of clinical oncology.

[14]  J. Woynarowski,et al.  Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). , 1999, Biochemical pharmacology.

[15]  R. Taetle,et al.  Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. , 1998, European journal of cancer.

[16]  D. Troyer,et al.  Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). , 1997, Biochemical pharmacology.

[17]  D. V. Von Hoff,et al.  Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. , 1997, Cancer research.

[18]  C. Osborne,et al.  Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. , 1992, European journal of cancer.

[19]  T. Mcmorris,et al.  Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity. , 1990, Journal of the National Cancer Institute.

[20]  M. Troner,et al.  Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial. , 1986, Cancer treatment reports.

[21]  J. Khandekar,et al.  Phase II study of cisplatin for metastatic prostatic carcinoma: An Eastern Cooperative Oncology Group Study , 1983, American journal of clinical oncology.

[22]  R. Fisher,et al.  Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. , 1979, Cancer treatment reports.

[23]  A. Guarino,et al.  Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. , 1977, Biochemical medicine.

[24]  W. Whitmore,et al.  Improvement of Cis‐dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model , 1977, Cancer.

[25]  A. Milam,et al.  Cone damage in patients receiving high-dose irofulven treatment. , 2005, Archives of ophthalmology.

[26]  A. Adjei,et al.  Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .